Propanc Biopharma submitted a request for an orphan drug designation with the US Food and Drug Administration (FDA) for PRP.

Propanc Biopharma (OTCQB:PPCB) submitted a request for an orphan drug designation with the US Food and Drug Administration (FDA) for PRP.
As quoted in the press release:

The proposed orphan drug indication for PRP is the treatment of ovarian cancer.
“Obtaining orphan drug designation from the FDA for our PRP therapy for ovarian cancer is a significant regulatory milestone that we are looking forward to, and will be a positive step forward in Propanc Biopharma’s ongoing efforts to develop effective treatments for metastatic cancer,” said James Nathanielsz, Propanc Biopharma’s Chief Executive Officer. “This will further reinforce our strategic investment in PRP, since we already achieved ODD status for pancreatic cancer, demonstrating significant progress in developing a potential best in class therapy that could transform treatment for patients with metastatic cancers, where limited treatment options are available.

Click here to read the full press release.

Source: www.marketwired.com

biopharma cancer cancers fda food and drug administration james nathanielsz odd orphan drug orphan drug designation ovarian cancer Pharmaceutical Investing